U.S. Wireless Telecom Stock News

Casey's General Stores (CASY) just delivered another quarter of earnings growth, powered by stronger prepared food and beverage sales and better grocery margins, and paired that with upbeat 2026 guidance and continued capital returns. See our latest analysis for Casey's General Stores. The latest earnings beat, upbeat 2026 guidance, store expansion plans, and steady buybacks help explain why Casey's 2025 year to date share price return sits around 40%, while its five year total shareholder...

Axos Financial (AX) has been catching more positive attention lately, with fresh upgrades from research services like Zacks and IBD highlighting its value profile and improving price performance relative to other bank stocks. See our latest analysis for Axos Financial. That improving sentiment seems to be feeding into the price action, with a roughly 9 percent 1 month share price return and a 25 percent year to date share price gain, alongside a powerful 3 year total shareholder return above...

KKR (KKR) has been drifting lower over the past week, but the bigger story is how the stock has swung from a strong past month to a weaker past 3 months and year. See our latest analysis for KKR. That mix of a recent 11.22% 1 month share price return and a weaker year to date share price return of 10.60 percent suggests momentum has cooled for now. Even so, the 3 year total shareholder return of 195.25 percent still points to a powerful longer term story. If KKR’s shifting momentum has you...

CTS (CTS) has drifted back into the spotlight as two years of slipping sales and earnings, roughly 3% annually on both, force investors to reassess how durable its sensor and actuator franchise really is. See our latest analysis for CTS. Even so, the recent 90 day share price return of 7.46% at a $44.52 share price contrasts with a 1 year total shareholder return of negative 19.74%. This hints that near term momentum is improving even as longer term holders remain underwater. If CTS’s mixed...

Recently, Tanger was upgraded to a Zacks Rank #2 (Buy) after analysts raised their earnings estimates, signaling improved expectations for the outlet-focused REIT. This shift in earnings outlook highlights how changing perceptions of Tanger’s underlying business momentum can quickly influence how investors view the company’s prospects. We’ll now examine how this upgrade, driven by improving earnings estimates, may reshape Tanger’s existing investment narrative and outlook. Rare earth metals...

Vertex Pharmaceuticals (VRTX) just delivered encouraging pediatric data for its gene editing therapy CASGEVY in sickle cell and beta thalassemia, and secured an FDA priority voucher that could accelerate review for children ages 5 to 11. See our latest analysis for Vertex Pharmaceuticals. Investors seem to be warming back up to that growth story, with Vertex’s share price at around $454.96 and a solid 90 day share price return of 17.52 percent. This is occurring even though the 1 year total...

Coca-Cola Consolidated (COKE) just lined up $1.35 billion in new senior unsecured term loans with Wells Fargo and others, refinancing a short term bridge facility and opening fresh room for shareholder friendly uses. See our latest analysis for Coca-Cola Consolidated. The financing news lands after a powerful run, with the latest $162.97 share price coming off a 90 day share price return of 37.49 percent and a five year total shareholder return of 545.35 percent, suggesting momentum remains...

In recent days, Gartner has drawn attention as a director bought 43,300 shares and the company executed a record US$1.00 billion stock buyback in Q3, while being added to the iSTOXX MUTB Global ESG Quality 200 index. These moves suggest leadership is signaling confidence and could attract incremental demand from ESG-focused investors at a time when AI-related business model risks remain in focus. Next, we’ll examine how this combination of insider buying and record buybacks may influence...

PennyMac Mortgage Investment Trust (PMT) has been quietly grinding higher, and that steady climb is starting to catch investors attention. With the stock up over the past 3 years, the question is whether this income focused REIT still offers value. See our latest analysis for PennyMac Mortgage Investment Trust. Over the past year, PennyMac Mortgage Investment Trust has seen only modest 1 year share price moves around its current 12.5 dollars level, but a solid 3 year total shareholder return...

Kimbell Royalty Partners (KRP) has quietly slipped about 17% over the past month and nearly 30% this year, putting the stock back on many income focused investors watchlists. See our latest analysis for Kimbell Royalty Partners. The recent slide in Kimbell Royalty Partners’ 30 day share price return of minus 16.6 percent caps a year to date share price return of nearly minus 30 percent, even as its five year total shareholder return of roughly 150 percent signals that long term momentum has...

In recent days, Rush Street Interactive announced a favorable tax development in Colombia that reduces regulatory uncertainty around its Latin American operations. This regulatory clarity has reinforced already optimistic analyst views on the company, highlighting Latin America as an increasingly important earnings driver. Next, we’ll examine how this reduced Colombian tax uncertainty affects Rush Street Interactive’s investment narrative, particularly its Latin American growth...

Adtalem Global Education has completed its previously announced US$150 million share repurchase, buying about 1.6 million shares, and on December 15, 2025, its Board authorized a new share buyback program of up to US$750 million through December 15, 2028. The jump in repurchase capacity suggests management sees meaningful value in reducing share count while still maintaining room to fund growth initiatives. We’ll now examine how this expanded US$750 million buyback authorization influences...

Brandes Small Cap Value Fund’s new stake in Prestige Consumer Healthcare (PBH), together with the company’s sizable buybacks and steady 2026 revenue guidance, has put fresh attention on this quietly evolving OTC portfolio story. See our latest analysis for Prestige Consumer Healthcare. Despite the new institutional interest, the short term picture is still cautious, with a negative year to date share price return alongside a weaker 1 year total shareholder return, even though the 5 year total...

We wouldn't blame MGP Ingredients, Inc. ( NASDAQ:MGPI ) shareholders if they were a little worried about the fact that...

We'd be surprised if NextNRG Inc. ( NASDAQ:NXXT ) shareholders haven't noticed that the Non-Independent Director...

Despite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...

Dave (DAVE) has climbed over the past year, even after a recent pullback, as investors reassess its subscription banking and cash-advance model in light of tightening consumer budgets and rising digital finance competition. See our latest analysis for Dave. With the share price now at $198.93, Dave’s strong year to date share price return of 130.48 percent and powerful three year total shareholder return of 2259.23 percent suggest that momentum has been rebuilding as investors re rate its...

Replimune Group, Inc. ( NASDAQ:REPL ) shareholders might have a reason to worry after multiple insiders sold their...

If you are wondering whether Tesla at around $489 a share is still a buy or already priced for perfection, you are not alone. This piece is designed to cut through the noise for you. Over the last week Tesla has climbed 10.0%, extending a 21.2% gain over the past month and a 29.2% rise year to date, even though the 1 year return sits at just 2.1% after a wild few years that saw the stock surge 255.5% over 3 years and 129.5% over 5 years. Some of that recent momentum has been tied to ongoing...

In December 2025, Abercrombie & Fitch promoted Robert J. Ball to Executive Vice President and Chief Financial Officer, while pushing ahead with collaborations like Olivia Culpo’s NFL-inspired capsule and major holiday sales events. These moves come as the company highlights very strong comparable sales growth, high gross margins, rapid earnings per share expansion aided by buybacks, and tighter inventory management supported by AI tools. Next, we’ll examine how this combination of strong...

Immatics N.V. recently completed a follow-on equity offering of 12,500,000 ordinary shares, raising US$125,000,000 at US$10 per share with a US$0.60 discount, expanding its capital base. This sizeable fundraising reshapes the company’s capital structure and may influence how investors view its ability to finance upcoming development priorities. We’ll now examine how this sizeable follow-on equity raise could influence Immatics’ investment narrative and future funding flexibility. Explore 28...

Protagonist Therapeutics and collaboration partner Takeda recently reported 52-week data from the pivotal Phase 3 VERIFY trial of rusfertide in polycythemia vera, showing durable hematocrit control without phlebotomy eligibility and a safety profile in line with prior results. The therapy’s multiple FDA designations, including Breakthrough Therapy and Orphan Drug, underscore its potential importance for patients who remain phlebotomy-dependent despite current standard treatments. We’ll now...

AXIS Capital Holdings’ board has recently declared a past quarterly common dividend of US$0.44 per share and a Series E 5.50% preferred dividend of US$34.375 per preferred share (US$0.34375 per depositary share), both payable on January 15, 2026 to holders of record on December 31, 2025. These dividend moves, alongside a stronger earnings outlook and favorable analyst sentiment, highlight growing investor confidence in AXIS’s income profile and business momentum. We’ll now examine how the...

DaVita Inc. recently appointed Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, expanding its leadership bench across talent, strategy, and innovation. These leadership changes highlight DaVita’s focus on culture, patient-centered care, and long-term strategy as it responds to operational and cost pressures. We’ll now examine how this leadership reshaping, alongside rising patient care costs, may influence DaVita’s broader investment narrative. AI...